Whitehawk Therapeutics, Inc. (Nasdaq: WHWK) is a clinical-stage oncology therapeutics company developing antibody-drug conjugate (ADC) cancer treatments, and its news flow reflects this focus on targeted oncology and biomarker-driven research. Company updates highlight progress across an advanced three-asset ADC portfolio targeting clinically validated proteins PTK7, MUC16 and SEZ6 in solid tumors.
Investors and observers following WHWK news will see announcements on key clinical and regulatory milestones, such as clearance of the Investigational New Drug (IND) application for the PTK7-targeted ADC HWK-007 and the submission of an IND for the MUC16-targeted ADC HWK-016. News also covers the start and design of Phase 1, multicenter, open-label trials in adults with advanced or metastatic solid tumors that are refractory to standard therapies, including initial evaluation in lung, ovarian and endometrial cancers for HWK-007 and high MUC16-expressing gynecologic cancers for HWK-016.
Whitehawk’s releases further include scientific updates, such as presentation of a real-world analysis confirming PTK7 as a broadly expressed, clinically relevant target across solid tumors at the AACR-NCI-EORTC conference, and collaboration announcements like its multi-year agreement with Tempus AI to support biomarker-driven oncology research. Corporate news items feature financial results, participation in healthcare and biotechnology investor conferences, and senior leadership appointments related to clinical development.
This WHWK news page aggregates these types of developments so readers can review regulatory updates, clinical trial progress, scientific presentations, collaborations and financial disclosures in one place. For those tracking ADC-focused oncology companies, it provides a centralized view of Whitehawk Therapeutics’ reported activities and milestones over time.
Whitehawk Therapeutics (NASDAQ: WHWK), an oncology therapeutics company focused on ADC cancer treatments, will participate in the Jefferies 2025 Global Healthcare Conference in New York City from June 3-5, 2025. CEO Dave Lennon will deliver a company overview presentation on June 4, 2025, from 2:00-2:30 PM ET. The presentation will be available via webcast on the company's IR website and accessible for replay for approximately 30 days after the event.
Whitehawk Therapeutics (NASDAQ: WHWK), an oncology therapeutics company focused on ADC cancer treatments, announced that its CEO Dave Lennon, PhD, will participate in a fireside chat at the TD Cowen 6th Annual Oncology Innovation Summit. The event is scheduled for May 28, 2025, at 2:30 PM ET. Investors can access the live webcast through Whitehawk's IR website, with the recording remaining available for approximately 30 days after the event.
[]Whitehawk Therapeutics (Nasdaq: WHWK) has successfully completed its strategic transformation by closing the sale of its Aadi Subsidiary to Kaken Pharmaceuticals for $100 million plus customary adjustments. The transaction, initially announced in December 2024, includes the transfer of Aadi Bioscience name, trademarks, and the FYARRO® business.
The company plans to utilize proceeds from both this divestiture and a recent $100M PIPE financing to advance its antibody drug conjugates (ADCs) portfolio and for general corporate purposes. The combined funding is projected to sustain operations until 2028, supporting key clinical data readouts for three assets.
Whitehawk Therapeutics (Nasdaq: WHWK), formerly Aadi Bioscience, announced its strategic transformation into an ADC-focused oncology company. The company will begin trading under the ticker 'WHWK' on March 19, 2025.
The company's portfolio includes three assets in-licensed from WuXi Biologics, utilizing HANGZHOU DAC's advanced ADC technology platform. These assets feature a stable linker delivering a Topoisomerase I inhibitor payload, targeting lung and ovarian cancers with minimal off-target toxicity.
Following recent developments, including a $100 million PIPE financing and pending divestiture of Aadi Subsidiary to Kaken Pharmaceuticals, Whitehawk expects cash reserves of $170-180 million, funding operations into 2028. The company reported Q4 2024 revenue of $7.2 million and full-year 2024 revenue of $26.0 million from FYARRO sales, with a Q4 net loss of $18.3 million and full-year net loss of $63.7 million.